



Axovant Sciences Ltd. Announces Pricing of \$125M Public Offering of Common Shares

April 11, 2017

BASEL, Switzerland, April 11, 2017 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON) ("Axovant"), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the pricing of its underwritten public offering of 6,742,179 of its common shares at a price to the public of \$18.54 per share. Gross proceeds to Axovant from the offering are expected to be approximately \$125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the common shares are being offered by Axovant. In connection with this offering, Axovant has granted the underwriters a 30-day option to purchase up to an additional 1,011,326 of its common shares on the same terms and conditions. The offering is expected to close on April 17, 2017, subject to customary closing conditions.

J.P. Morgan, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering. JMP Securities, Baird and H.C. Wainwright & Co. are acting as co-managers.

A shelf registration statement relating to the offered common shares was filed with the Securities and Exchange Commission (SEC), and was declared effective on January 13, 2017. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website, located at www.sec.gov. Copies of the final prospectus supplement and accompanying base prospectus related to the offering may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, toll-free: (866) 803-9204, email: prospectus-req_fi@jpmchase.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (212) 336-7460, e-mail: Prospectus_Department@Jefferies.com.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities, and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.

About Axovant

Axovant Sciences is a leading clinical-stage neurology company focused on the treatment of dementia and related neurological disorders. Axovant is developing a pipeline of product candidates to comprehensively address the cognitive, functional, and behavioral aspects of dementia. Our vision is to become the leading company focused on the treatment of dementia by broadly addressing multiple forms of this condition through developing innovative new medicines for patients.

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/axovant-sciences-ltd-announces-pricing-of-125m-public-offering-of-common-shares-300437874.html>

SOURCE Axovant Sciences Ltd.

Contact:

Jonathan Neely
Head, Investor Relations and Corporate Communications
Axovant Sciences, Inc.
(212) 634-9744